FDA Asks Genentech To Add Boxed Anaphylaxis Warning To Xolair Label
This article was originally published in The Pink Sheet Daily
Executive Summary
Continued post-marketing reports of anaphylaxis, some well after treatment, led agency to ask for label revision.